JPRN-UMIN000009620已完成未知
Assessment of efficy and safety of everolimus in Japanese patients with mRCC - Assessment of efficy and safety of everolimus
Tokyo Afinitor Clinical Trial Group0 个研究点目标入组 200 人开始时间: 2013年1月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Unsuitable for everolimus treatment
研究者
相似试验
进行中（未招募）
1 期
EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study.• Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung• Well to moderately differentiated neuroendocrine carcinoma (NET G1/G2) that switched to G3 (confirmed by histology)• Neuroendocrine tumor G3 (NET G3)EUCTR2012-004550-28-DEAIO-Studien-gGmbH
招募中
4 期
Efficiency of everolimus for the treatment of kidney transplanted patients presenting a rejection2024-513814-37-00Hospices Civils De Lyon20
招募中
Unknown
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
已完成
不适用
Safety and Efficacy of a Single 48 mm Everolimus-Eluting Stent in Percutaneous Coronary Intervention for Diffuse Coronary Lesions: A propensity score analysisCoronary Artery DiseaseJPRN-UMIN000047934agano Municipal Hospita130
招募中
不适用
The assessment of the response to everolimus of renal cell carcinoma by FDG PET/CT and its impact on prognosisadvanced renal cell carcinoma (RCC)JPRN-UMIN000011570Yokohama City University30